Voyager Therapeutics Inc Stock Price, News & Analysis

Voyager Therapeutics (Nasdaq: VYGR) has announced employment agreements with two new hires that will include non-qualified stock options and restricted stock units. The stock option awards were approved by Voyager's Compensation Committee and became effective on January 23, 2023. One employee received options for 100,000 shares and restricted stock units for 50,000 shares, while the other employee received options for 50,000 shares and restricted units for 25,000 shares. Each stock option has a ten-year term with an exercise price of $9.16 per share. Vesting for these equity awards is tied to continued employment.

Voyager Therapeutics has entered a strategic collaboration with Neurocrine Biosciences to develop gene therapies for neurological diseases, including Parkinson's disease. The deal includes an up-front payment of $175 million, comprising $39 million in equity and potential milestone payments of up to $1.5 billion. Voyager retains options for co-development in the U.S. and will receive royalties on net sales, while Neurocrine acquires rights to multiple therapies. Jude Onyia from Neurocrine will join Voyager's Board of Directors.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology firm focused on gene therapy, will have its CEO, Alfred W. Sandrock, Jr., present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET. The presentation will be available via webcast on the company's website and archived for 30 days. Voyager is known for its TRACER™ AAV capsid discovery platform, aiming to enhance gene therapy delivery, with ongoing projects in Alzheimer's, ALS, Parkinson's, and Friedreich's Ataxia.

Voyager Therapeutics (Nasdaq: VYGR) has appointed Grace E. Colón, Ph.D., to its Board of Directors effective January 1, 2023. With over 25 years of experience in healthcare and biotech, Dr. Colón previously served as President and CEO of InCarda Therapeutics. Her leadership experience includes pivotal roles at Precigen and Gilead Sciences. The CEO of Voyager, Alfred W. Sandrock, emphasized that Dr. Colón's operational insights will be valuable as the company progresses its neurology and gene therapy initiatives. Voyager aims to overcome gene therapy delivery challenges and has a pipeline targeting conditions like Parkinson's and Alzheimer’s.

Voyager Therapeutics (Nasdaq: VYGR) has announced an employment agreement for a new hire, which includes grants of stock options and restricted stock units. The stock option allows the purchase of 54,000 shares at an exercise price of $5.57, vesting over four years. Additionally, 27,000 restricted stock units will vest annually over three years starting January 1, 2023. These equity awards aim to attract talent essential for Voyager's advancements in gene therapy and neurology. The company's TRACER platform aims to enhance gene therapy delivery targeting neurological diseases.

Voyager Therapeutics reported third quarter 2022 results, highlighting a significant validation of its TRACERTM capsid platform after Pfizer exercised its licensing option for a novel capsid, resulting in a $10 million payment. Collaboration revenue surged to $41.1 million, compared to $1.5 million in Q3 2021. Net income stood at $17.6 million, reversing a loss from the previous year. R&D expenses increased to $19.3 million, while G&A costs decreased. Voyager expects to maintain sufficient cash flow through 2024, supported by collaboration agreements.

Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced it will disclose its third-quarter 2022 financial and operational results before the market opens on November 8, 2022. Following the results, a live conference call and webcast will occur at 8:30 a.m. ET to discuss the findings. Interested participants can register for the call to receive dial-in details and access a live webcast on Voyager's investor website. Voyager is focused on next-generation AAV gene therapy, aiming to treat debilitating diseases using its proprietary capsids from the TRACER™ discovery platform.

Voyager Therapeutics (Nasdaq: VYGR) recently announced an employment agreement with a new hire, which includes inducement awards approved by its Compensation Committee. The agreement comprises a non-qualified stock option for 60,000 shares and restricted stock units for 30,000 shares. The stock option has a ten-year term with an exercise price of $6.01 per share and vests over four years. The restricted stock units will vest annually over three years, starting on the first anniversary of the effective date, which is set for January 1, 2023.

Voyager Therapeutics (Nasdaq: VYGR) presented significant findings at the European Society of Gene & Cell Therapy (ESGCT) Congress 2022. The data revealed a novel cell surface receptor that enhances the delivery of Voyager's TRACER AAV capsids across the blood-brain barrier (BBB), showing potential for human translation. Additionally, preclinical results indicate ultra-low dosing might achieve therapeutic effects with reduced toxicity. These advancements could transform CNS drug delivery, underscoring Voyager's commitment to addressing critical neurological disorders.